ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
보체 억제제 시장 규모는 향후 수년간 비약적인 성장이 전망됩니다. 2029년에는 CAGR 39.3%로 성장할 전망이며, 617억 4,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 자가면역질환 및 염증성 질환 이환율 상승, 생물제제 및 바이오시밀러 시장 확대, 임상시험 수 증가, 장시간 작용형 보체 억제제 개발, 신흥국 시장의 헬스케어 인프라 개선, 표적요법 채택 확대, 노인인구 증가, 생물제제 치료에 대한 환자 접근성 강화 등에 기인할 것으로 보입니다. 이 기간에 예상되는 주요 동향으로는 창약에서 인공지능 통합, 고급 바이오마커 동정 기술, 환자 반응을 예측하기 위한 머신러닝, 장시간 작용형 제제, 보체계 해석을 위한 차세대 시퀀서, 하이 처리량 스크리닝 플랫폼, 보체 억제 시험을 위한 장기 온칩 모델, 보체 억제제 개발을 위한 3D 바이오 프린팅, 치료 효과를 평가하기 위한 실시간 모니터링 도구 등이 있습니다.
맞춤형 의료에 대한 관심 증가는 향후 수년간 보체 억제제 시장의 성장을 가속할 것으로 예측됩니다. 맞춤형 의료에는 치료 결과를 최적화하고 치료를 개선하기 위해 유전적, 환경적, 라이프스타일적 요인에 따라 개별 환자 맞춤형 치료를 시행하는 것이 포함됩니다. 맞춤형 의료의 채용이 증가하고 있는 배경에는, 유전체학의 진보, 바이오 마커에 근거하는 진단의 이용 가능성 확대, 데이터 분석 기술 향상, 보다 과녁을 좁힌 효과적인 치료에 대한 수요의 고조 등이 있습니다. 보체 억제제는 환자 고유의 질환 프로파일, 유전자 구성, 보체 활성 수준을 기반으로 보체계의 특정 구성요소를 표적으로 함으로써 맞춤형 의료와 연계됩니다. 예를 들어 2024년 2월 미국 비영리단체인 개별화의료연합(PMC)은 미국 식품의약국(FDA)이 2023년 26개의 새로운 개별화 의약품을 승인했다고 보고했습니다. 그 결과, 맞춤형 의료에 대한 주목의 고조가 보체 억제제 시장의 성장을 뒷받침하고 있습니다.
보체 억제제 시장의 주요 기업은 다양한 자가면역 질환 및 염증성 질환에서 보체계를 효과적으로 제어하는 단일클론항체의 개발을 점점 더 진행하고 있습니다. 단일클론항체는 암, 자가면역질환, 감염병 등의 치료를 돕기 위해 항원을 특이적으로 표적으로 하여 결합하도록 설계된 실험실에서 설계된 단백질입니다. 예를 들면, 스위스의 제약회사 F. 호프만 라 로슈사는 2024년 8월, 유럽 위원회로부터, C5 저해제에 의한 치료력이 있는, 또는 치료력이 없는 발작성 야간 헤모글로빈뇨증(PNH)의 성인 및 청년을 대상으로 디자인된 단클론항체인 피아스키(클로발리맙)의 승인을 취득했습니다. 피어스 키(클로바리맙)는 보체 단백질 C5를 표적으로 하여 그 절단을 저해함으로써 막 공격 복합체(MAC)의 형성을 저해하고 종말 보체를 통한 혈관 내 용혈을 억제합니다. 이 메커니즘을 통해 헤모글로빈 수치가 개선되고 수혈의 필요성이 감소하며 피로와 빈혈 등의 증상이 완화되고 결국 환자의 QOL이 향상됩니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장-거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 보체 억제제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 보체 억제제 시장 : 성장률 분석
세계의 보체 억제제 시장 실적 : 규모 및 성장(2019-2024년)
세계의 보체 억제제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 보체 억제제 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 보체 억제제 시장 : 제품 유형별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
보체 성분 3(C3) 억제제
보체 성분 5(C5) 억제제
보체 인자 D 억제제
세계의 보체 억제제 시장 : 작용기전별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
대체 경로 억제제
고전적 경로 억제제
렉틴 경로 억제제
세계의 보체 억제제 시장 : 적응증별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
비전형 용혈성 요독증후군(aHUS)
전신성 중증근무력증(gMG)
발작성 야간 혈색소뇨증(PNH)
세계의 보체 억제제 시장 : 투여 경로별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
정맥내(IV)
피하(SC)
세계의 보체 억제제 시장 : 환자 인구 통계별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
성인용
고령자
소아과
세계의 보체 억제제 시장 : 보체 성분 3(C3) 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
저분자 C3 억제제
단일클론항체 C3 억제제
펩티드계 C3 억제제
세계의 보체 억제제 시장 : 보체 성분 5(C5) 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
단일클론항체 C5 억제제
저분자 C5 억제제
RNA 기반 C5 억제제
세계의 보체 억제제 시장 : 보체 인자 D 억제제 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
소분자 인자 D 억제제
단일클론항체 인자 D 억제제
제7장 지역별 및 국가별 분석
세계의 보체 억제제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 보체 억제제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
보체 억제제 시장 : 경쟁 구도
보체 억제제 시장 : 기업 프로파일
F. Hoffmann-La Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Amgen Inc.
Regeneron Pharmaceuticals Inc.
Astellas Pharma Inc.
CSL Behring
UCB SA
Takeda Pharmaceutical Company Limited
Alnylam Pharmaceuticals Inc.
Innovent Biologics Inc.
BioCryst Pharmaceuticals Inc.
Pharming Group NV
Apellis Pharmaceuticals Inc.
Omeros Corporation
Akari Therapeutics Plc
InflaRx NV
Kira Pharmaceuticals
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
보체 억제제 시장(2029년) : 새로운 기회를 제공하는 국가
보체 억제제 시장(2029년) : 새로운 기회를 제공하는 부문
보체 억제제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Complement inhibitors are therapeutic agents designed to regulate or block the complement system, a crucial part of the immune response involved in inflammation, pathogen elimination, and cell lysis. These inhibitors target specific complement components, such as complement component 3 (C3) or complement component 5 (C5), to prevent overactivation and reduce tissue damage in conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
The key product types in the complement inhibitors market include complement component 3 (C3) inhibitors, complement component 5 (C5) inhibitors, and complement factor D inhibitors. C3 inhibitors are therapeutic agents that block the activation of C3, a central protein in the complement cascade. The mechanisms of action for complement inhibitors involve alternative pathway inhibitors, classical pathway inhibitors, and lectin pathway inhibitors. These therapies are used to treat conditions such as aHUS, generalized myasthenia gravis (GMG), and PNH. Administration routes include intravenous (IV) and subcutaneous (SC) methods, serving a broad patient demographic, including adults, geriatrics, and pediatrics.
The complement inhibitors market research report is one of a series of new reports from The Business Research Company that provides complement inhibitors market statistics, including complement inhibitors industry global market size, regional shares, competitors with a complement inhibitors market share, detailed complement inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the complement inhibitors industry. This complement inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The complement inhibitors market size has grown exponentially in recent years. It will grow from $16.41 billion in 2024 to $21.43 billion in 2025 at a compound annual growth rate (CAGR) of 30.6%. The growth during the historic period can be attributed to the increasing prevalence of complement-mediated diseases, rising awareness of rare diseases, the emergence of biologics as effective therapies, growing healthcare expenditure, a stronger focus on personalized medicine, the availability of orphan drug incentives, regulatory support for rare disease treatments, and enhanced collaborations between pharmaceutical companies and research institutions.
The complement inhibitors market size is expected to see exponential growth in the next few years. It will grow to $61.74 billion in 2029 at a compound annual growth rate (CAGR) of 39.3%. The growth in the forecast period can be attributed to the rising incidence of autoimmune and inflammatory diseases, expansion of the biologics and biosimilars markets, an increasing number of clinical trials, the development of longer-acting complement inhibitors, improved healthcare infrastructure in emerging markets, greater adoption of targeted therapies, a growing geriatric population, and enhanced patient access to biologic treatments. Key trends expected during this period include the integration of artificial intelligence in drug discovery, advanced biomarker identification techniques, machine learning for predicting patient responses, long-acting drug formulations, next-generation sequencing for complement system analysis, high-throughput screening platforms, organ-on-a-chip models for complement inhibition testing, 3D bioprinting for complement inhibitor development, and real-time monitoring tools for assessing treatment efficacy.
The increasing focus on personalized medicine is expected to drive the growth of the complement inhibitors market in the coming years. Personalized medicine involves tailoring treatments to individual patients based on their genetic, environmental, and lifestyle factors to optimize outcomes and improve care. The rising adoption of personalized medicine is fueled by advancements in genomics, the growing availability of biomarker-based diagnostics, improved data analytics technologies, and a growing demand for more targeted and effective therapies. Complement inhibitors align with personalized medicine by targeting specific components of the complement system based on a patient's unique disease profile, genetic makeup, and complement activity levels. For instance, in February 2024, the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, reported that the U.S. Food and Drug Administration (FDA) approved 26 new personalized medicines in 2023, a notable increase from 12 approvals in 2022. As a result, the expanding focus on personalized medicine is fueling the growth of the complement inhibitors market.
Leading companies in the complement inhibitors market are increasingly developing monoclonal antibodies to effectively regulate the complement system in various autoimmune and inflammatory diseases. Monoclonal antibodies are lab-engineered proteins designed to specifically target and bind to antigens, aiding in the treatment of conditions such as cancer, autoimmune disorders, and infections. For example, in August 2024, F. Hoffmann-La Roche AG, a Switzerland-based pharmaceutical company, received approval from the European Commission for PiaSky (crovalimab), a monoclonal antibody designed for adults and adolescents with paroxysmal nocturnal hemoglobinuria (PNH) who are either new to or previously treated with C5 inhibitors. PiaSky (crovalimab) targets complement protein C5 to prevent its cleavage, thereby inhibiting the formation of the membrane attack complex (MAC) and reducing terminal complement-mediated intravascular hemolysis. This mechanism helps improve hemoglobin levels, decrease the need for blood transfusions, and alleviate symptoms such as fatigue and anemia, ultimately enhancing patients' quality of life.
In September 2023, Magenta Therapeutics Inc., a US-based clinical-stage biotechnology company, merged with Dianthus Therapeutics Inc. for an undisclosed amount. This merger enables the combined company to focus on advancing Dianthus' pipeline of next-generation complement inhibitors, including DNTH103, which is currently in a Phase I clinical trial. Dianthus Therapeutics Inc. is a US-based clinical-stage biotechnology company specializing in developing next-generation antibody complement therapeutics for severe autoimmune diseases.
Major players in the complement inhibitors market are F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., CSL Behring, UCB S.A., Takeda Pharmaceutical Company Limited, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., BioCryst Pharmaceuticals Inc., Pharming Group N.V., Apellis Pharmaceuticals Inc., Omeros Corporation, Akari Therapeutics Plc, InflaRx N.V., Kira Pharmaceuticals.
North America was the largest region in the complement inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in complement inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the complement inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The complement inhibitors market consists of sales of small molecule inhibitors, recombinant proteins and biologics designed to regulate the complement system and treat complement-mediated diseases. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Complement Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on complement inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for complement inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The complement inhibitors market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Complement Component 3 (C3) Inhibitors; Complement Component 5 (C5) Inhibitors; Complement Factor D Inhibitors
2) By Mechanism Of Action: Alternative Pathway Inhibitors; Classic Pathway Inhibitors; Lectin Pathway Inhibitors
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Complement Inhibitors Market Characteristics
3. Complement Inhibitors Market Trends And Strategies
4. Complement Inhibitors Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market
5. Global Complement Inhibitors Growth Analysis And Strategic Analysis Framework
5.1. Global Complement Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Complement Inhibitors Market Growth Rate Analysis
5.4. Global Complement Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Complement Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Complement Inhibitors Total Addressable Market (TAM)
6. Complement Inhibitors Market Segmentation
6.1. Global Complement Inhibitors Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Complement Component 3 (C3) Inhibitors
Complement Component 5 (C5) Inhibitors
Complement Factor D Inhibitors
6.2. Global Complement Inhibitors Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Alternative Pathway Inhibitors
Classic Pathway Inhibitors
Lectin Pathway Inhibitors
6.3. Global Complement Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Atypical Hemolytic Uremic Syndrome (aHUS)
Generalized Myasthenia Gravis (gMG)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
6.4. Global Complement Inhibitors Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous (IV)
Subcutaneous (SC)
6.5. Global Complement Inhibitors Market, Segmentation By Patient Demographics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adult
Geriatric
Pediatric
6.6. Global Complement Inhibitors Market, Sub-Segmentation Of Complement Component 3 (C3) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule C3 Inhibitors
Monoclonal Antibody C3 Inhibitors
Peptide-Based C3 Inhibitors
6.7. Global Complement Inhibitors Market, Sub-Segmentation Of Complement Component 5 (C5) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibody C5 Inhibitors
Small Molecule C5 Inhibitors
RNA-Based C5 Inhibitors
6.8. Global Complement Inhibitors Market, Sub-Segmentation Of Complement Factor D Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Small Molecule Factor D Inhibitors
Monoclonal Antibody Factor D Inhibitors
7. Complement Inhibitors Market Regional And Country Analysis
7.1. Global Complement Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Complement Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
